We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an...
Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies Appili...
FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701...
Additional US$6.6 million funding commitment for ATI-1701 brings the total program funding awarded to approximately US$14 million These funds along with other potential funding sources, are...
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the...
The morning opened up on a high note for this dually-listed company as it announced U.S. Food and Drug Administration (FDA) approval of its Metronidazole Oral Suspension 500mg/5mL ( ATI-1501 ) To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 14.2857142857 | 0.035 | 0.04 | 0.035 | 45320 | 0.04 | CS |
4 | 0.01 | 33.3333333333 | 0.03 | 0.06 | 0.03 | 566834 | 0.04419516 | CS |
12 | 0.015 | 60 | 0.025 | 0.06 | 0.025 | 232526 | 0.0410231 | CS |
26 | 0 | 0 | 0.04 | 0.06 | 0.025 | 166445 | 0.03823474 | CS |
52 | 0 | 0 | 0.04 | 0.08 | 0.025 | 207681 | 0.04691898 | CS |
156 | -0.99 | -96.1165048544 | 1.03 | 1.31 | 0.025 | 193413 | 0.16301461 | CS |
260 | -1.09 | -96.4601769912 | 1.13 | 1.6 | 0.025 | 182573 | 0.29560205 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions